Supporting Information: Efficient Screening of Coformers for Active Pharmaceutical Ingredient Cocrystallization

Isaac J. Sugden*,1,# Doris E. Braun*,2,# David H. Bowskill, 1 Claire S. Adjiman1 and Constantinos C. Pantelides¹

1. Molecular Systems Engineering Group, Department of Chemical Engineering, Centre for Process Systems Engineering, Institute for Molecular Science and Engineering, Imperial College London London SW7 2AZ, United Kingdom

2. University of Innsbruck, Institute of Pharmacy, Pharmaceutical Technology, Josef-Moeller-Haus, Innrain 52c, A-6020, Innsbruck, Austria

*Co-corresponding authors.

[#]These two authors contributed equally.

CPU cost breakdown 1

1.1 Single component investigations

Breakdown of CPU cost (CPU hours)									
	CrystPred				CrystOpt				
API	LAMs	Global	Analysis	Clustering	refinements	Total			
PARACETAMOL	1086.05	827.23	9.77	1.10	4132.59	6056.75			
ASPIRIN	3837.39	463.20	10.79	3.80	2763.00	7078.18			
CARBAMAZAPENE	37.22	729.36	4.86	1.00	4342.00	5114.45			

1.2 Cocrystal investigations

structure Glo		Analysis	Clustering	refinements	refinement	Total						
Aspirin												
OXALAC	804	2	1	472	1717	2524						
DUPKAB	4854	0	3	492	5445	10302						
SUCACB	1129	0	0	497	2595	3724						
CEBGOF	868	0	0	492	3444	4312						
PYRDNA	954	2	1	499	1780	2737						
TELZOZ	1292	0	0	498	3852	5144						
NICOAM	1246	1	1	490	4075	5323						
BITZAF	3130	0	3	491	1568	4701						
NICOAC	1673	0	0	499	5556	7230						
ESALUF	2317	17	2	495	3010	5347						
		Carbama	zepine									

1

OXALAC	1020	72	0	500	3221	4313
DUPKAB	3871	6	40	471	3306	7224
SUCACB	1644	18	0	266	1417	3079
CEBGOF	2395	55	5	499	3881	6335
PYRDNA	829	2	0	401	2851	3682
TELZOZ	958	0	3	500	3860	4822
NICOAM	1644	0	1	363	1364	3008
BITZAF	3596	1	7	308	5101	8706
NICOAC	1580	0	14	499	2063	3657
ESALUF	3384	57	14	499	3996	7451
ASPIRIN	5995	0	13	328	3630	9639
		Paracetamo	1			
OXALAC	1005	1	19	34	96	1120
OXALAC DUPKAB	1005 3708	1 1	19 7	34 483	96 2870	1120 6585
OXALAC DUPKAB SUCACB	1005 3708 868	1 1 2	19 7 31	34 483 499	96 2870 1647	1120 6585 2548
OXALAC DUPKAB SUCACB CEBGOF	1005 3708 868 1221	1 1 2 1	19 7 31 10	34 483 499 415	96 2870 1647 1638	1120 6585 2548 2870
OXALAC DUPKAB SUCACB CEBGOF PYRDNA	1005 3708 868 1221 2297	1 1 2 1 23	19 7 31 10 0	34 483 499 415 197	96 2870 1647 1638 915	1120 6585 2548 2870 3235
OXALAC DUPKAB SUCACB CEBGOF PYRDNA TELZOZ	1005 3708 868 1221 2297 1056	1 1 2 1 23 0	19 7 31 10 0 5	34 483 499 415 197 499	96 2870 1647 1638 915 2753	1120 6585 2548 2870 3235 3815
OXALAC DUPKAB SUCACB CEBGOF PYRDNA TELZOZ NICOAM	1005 3708 868 1221 2297 1056 791	$ \begin{array}{c} 1 \\ 1 \\ 2 \\ 1 \\ 23 \\ 0 \\ 3 \end{array} $	19 7 31 10 0 5 15	34 483 499 415 197 499 475	96 2870 1647 1638 915 2753 3267	1120 6585 2548 2870 3235 3815 4076
OXALAC DUPKAB SUCACB CEBGOF PYRDNA TELZOZ NICOAM BITZAF	1005 3708 868 1221 2297 1056 791 5249	$ \begin{array}{c} 1 \\ 1 \\ 2 \\ 1 \\ 23 \\ 0 \\ 3 \\ 3 \end{array} $	19 7 31 10 0 5 15 0	34 483 499 415 197 499 475 204	96 2870 1647 1638 915 2753 3267 978	1120 6585 2548 2870 3235 3815 4076 6230
OXALAC DUPKAB SUCACB CEBGOF PYRDNA TELZOZ NICOAM BITZAF NICOAC	1005 3708 868 1221 2297 1056 791 5249 789	$ \begin{array}{c} 1 \\ 1 \\ 2 \\ 1 \\ 23 \\ 0 \\ 3 \\ 3 \\ 4 \end{array} $	19 7 31 10 0 5 15 0 27	34 483 499 415 197 499 475 204 500	96 2870 1647 1638 915 2753 3267 978 1739	1120 6585 2548 2870 3235 3815 4076 6230 2559

1.3 Computing quantity $\Delta\Delta U_c$

Table S	2. sinal	e crystal	CSP regults	

Table S3: single crystal CSP results								
System	lowest experimental energy (kJ/mol)	Global Minimum (kJ/mol)						
PARA	-114.405	-114.405						
ASPI	-114.058	-114.058						
CARB	-128.32	-129.947						
BITZ	-127.253	-133.198						
CEGB	-99.6216	-99.6216						
DUPK	-112.607	-112.607						
ESAL	-91.448	-94.3638						
NICC	-100.044	-100.044						
NICM	-100.317	-100.317						
OXAL	-70.5857	-70.5857						
PYRD	-60.4391	-58.9266						
SUCA	-102.046	-102.046						
TELZ	-114.033	-115.753						

Table S4: Cocrystal CSP results and $\Delta\Delta U_c$ calculation with either scheme (all values in kJ/mol)								
	API exptal							
	energy	API						
	+coformer	exptal						
	exptal	energy +	Cocrystal	solvate	$\Delta\Delta U_{c}$	$\Delta\Delta U_{c}$		
System	energy	coformer	energy	correction	(approach 1)	(approach 2)		

		GM				
DIDI		energy				
PARA- BITZ	-241.659	-247.604	-239.915	0	1.7434	7.6887
PARA-						
CEBG	-214.027	-214.027	-209.705	0	4.3225	4.3225
PARA-						
DUPK	-227.012	-227.012	-219.217	0	7.79575	7.79575
PARA-	205 853	208 760	106 186	0	0 6675	12 5822
$PARA_{-}$	-205.855	-200.709	-190.100	0	9.0075	12.3655
NICC	-214.45	-214.45	-204.907	0	9.5424	9.5424
PARA-				-		
NICM	-214.723	-214.723	-214.198	0	0.5248	0.5248
PARA-						
OXAL	-184.991	-184.991	-188.554	0	-3.5631	-3.5631
PARA-	121 224	152.222	177 105	2.5	2 0 1 0 4	1.0505
PYRD	-1/1.//4	-1/3.332	-1//.185	2.5	-2.9104	-1.3525
PARA- SUCA	-216.452	-216.452	-198.819	0	17.6324	17.6324
PARA-						
TELZ	-228.438	-230.158	-232.549	0	-4.1106	-2.3908
ASPI-						
BITZ	-241.311	-247.256	-203.893	0	37.4178	43.3631
ASPI-	212.69	212.69	202 004	0	0.686	0.686
	-215.08	-215.08	-203.994	0	9.080	9.080
DUPK	-226.665	-226.665	-213.887	0	12.77795	12,77795
ASPI-			2101007	Ŭ	120000	1200000
ESAL	-205.506	-208.422	-195.11	0	10.3959	13.3117
ASPI-						
NICC	-214.102	-214.102	-200.377	0	13.725	13.725
ASPI-	214 275	014 075	207 (14	0	(7(1)	(7(1)
NICM A SDI	-214.375	-214.375	-207.614	0	0./013	0./013
OXAL	-184 644	-184 644	-189 181	0	-4 5378	-4 5378
ASPI-	10.0011	10.0011	10,1101	Ŭ		
PYRD	-171.427	-172.985	-181.3	2.5	-7.3737	-5.8158
ASPI-						
SUCA	-216.104	-216.104	-202.182	0	13.9226	13.9226
ASPI-				0		= 100 (
TELZ	-228.091	-229.811	-222.617	0	5.4738	7.1936
CARB- BITZ	-255.573	-261.518	-251.738	0	3.8348	9.7801
CARB-						
CEBG	-227.941	-227.941	-230.526	0	-2.5843	-2.5843
CARB-						
DUPK	-240.927	-240.927	-243.73	0	-2.80365	-2.80365
CARB-	010 500	000 604	010.000	~	0.025	2 00000
ESAL	-219.768	-222.684	-219.803	0	-0.035	2.8808

CARB- NICC	-228.364	-228.364	-224.067	0	4.297	4.297
CARB- NICM	-228.637	-228.637	-226.569	0	2.06774	2.06774
CARB- OXAL	-198.905	-198.905	-211.832	0	-12.9269	-12.9269
CARB- PYRD	-185.688	-187.246	-192.044	2.5	-3.8559	-2.298
CARB- SUCA	-230.366	-230.366	-230.978	0	-0.612	-0.612
CARB- TELZ	-242.353	-244.073	-250.954	0	-8.6016	-6.8818
CARB- ASPI	-242.378	-244.005	-237.386	0	4.9916	6.6193

2 EXPERIMENTAL

2.1 *cis* Aconitic acid (form II)

Slurry experiments of the commercial sample in *n*-heptane, dichloromethane or diethyl ether resulted in form II. The experimental PXRD pattern of the *cis* aconitic acid form II indexed to the monoclinic space group C2/c, with Z'=1 (**Figure 1**.a). The unit cell and space group symmetry are distinct from the already known structure of *cis* aconitic acid form I (*Pbca*, Z'=1). The molecular conformations present in the two *cis* aconitic acid polymorphs differ substantially. In form I one of the acid groups forms an intramolecular O–H···O hydrogen bonding interaction to a second carboxylic acid function (**Figure 1**.b). This is in contrast to form II, where all three of the carboxylic acid protons form intermolecular interactions. Five strong hydrogen bonding interactions are formed in form I, one carboxylic acid dimer $[(R_2^2(8)]^{-1}, \text{ one } C_1^1(7) \text{ chain and the intramolecular hydrogen bond. The second$ $polymorph forms six hydrogen bonding interactions, two <math>R_2^2(8)$ dimers one $C_1^1(7)$ chain motif with all interactions being O–H···O (**Figure 1**.c). Furthermore, C–H···O close contacts stabilise the structure.



Figure 1. (a) Observed (black points), calculated (red line) and difference profiles (green) for the Rietveld refinements of *cis* aconitic acid form II. Blue tick marks denote the peak positions. (b) Conformation found in the two *cis* aconitic acid polymorphs. Note one of the COOH function of form II might be disordered, i.e. 180° flip of the acid function marked with an ellipsoid. (c) Packing diagram of *cis* aconitic acid form II viewed along the *b* crystallographic axis.

Finally, the *cis* aconitic acid pure form investigation is slightly different. Experimental indications suggested that the intramolecular hydrogen bond may be broken, necessitating broadening the search ranges, as the initial investigation had assumed the intramolecular hydrogen bond was maintained.

2.2 Paracetamol (PARA) cocrystal screen

The oxalic acid cocrystal (PARA-OXAL) and pyridine solvate (PARA-PYRD) were both successfully reproduced.

An overview over the paracetamol crystallization experiments is given in Table S1 and selected PXRD diffractograms are shown in Figure S1 - Figure S10.

Table S1. Overview paracetamol crystallization results.								
Coformer	Contact	Slurry experiments			Liquid-as	sisted grinding	Co-	
	Preparation						sublimation	
		<i>n</i> -Heptane	Pyridine	Diethyl ether	<i>n</i> -heptane	Diethyl ether		

Pyridoxine	X	Х	n. a.	Х	X	Х	Х
Methyl parabene	х	x	n. a.	х	X	х	х
Propyl parabene	х	x	n. a.	х	X	х	х
t-Butyl-4-	х	X	n. a.	х	Х	х	х
hydroxyanisole							
Nicotinic Acid	n. a.	x	n. a.	х	Х	х	х
Nictoinamide	х	x	n. a.	х	Х	х	Х
Oxalic Acid	n. a.	yes	n. a.	yes	yes	yes	yes
Succinic Acid	х	x	n. a.	х	X	х	х
cis-Aconitic	n. a.	x	n. a.	х	X	х	Х
Acid							
Pyridine	n. a.	n. a.	yes	n. a.	n. a.	n. a.	n. a.

n.a. – not attempted, yes – cocrystal/solvate formation, x – physical mixture of the two compounds.



Figure S1. Comparison of experimental and from single crystal structure data simulated PXRD patterns of paracetamol (red), **pyridoxine** and a physical mixture obtained from LAG grinding experiments.



Figure S2. Comparison of experimental and from single crystal structure data simulated PXRD patterns of paracetamol (red), methyl paraben and a physical mixture obtained from LAG grinding experiments.



Figure S3. Comparison of experimental and from single crystal structure data simulated PXRD patterns of paracetamol (red), propyl paraben and a physical mixture obtained from LAG grinding experiments.



Figure S4. Comparison of experimental and from single crystal structure data simulated PXRD patterns of paracetamol (red), **t-butyl-4-hydroxyanisole** and a physical mixture obtained from LAG grinding experiments.



Figure S5. Comparison of experimental and from single crystal structure data simulated PXRD patterns of paracetamol (red), **nicotinic acid** and a physical mixture obtained from LAG grinding experiments.



Figure S6. Comparison of experimental and from single crystal structure data simulated PXRD patterns of paracetamol (red), **nicotinamide** and a physical mixture obtained from LAG grinding experiments.



Figure S7. Comparison of experimental and from single crystal structure data simulated PXRD patterns of paracetamol (red), **oxalic acid** and the cocrystal obtained in co-sublimation experiments.



Figure S8. Comparison of experimental and from single crystal structure data simulated PXRD patterns of paracetamol (red), **succinic acid** and a physical mixture obtained from LAG grinding experiments.



Figure S9. Comparison of experimental and from single crystal structure data simulated PXRD patterns of paracetamol (red), **cis-aconitic acid** and a physical mixture obtained from LAG grinding and crystallisation experiments.



Figure S10. Comparison of experimental and from single crystal structure data simulated PXRD patterns of paracetamol (red) and the pyridine solvate of APAP.

2.3 Acetylsalicylic Acid (ASPI) cocrystal screen

No multicomponent forms were obtained using the chosen coformers/solvents (Table S2, Figure S11 - Figure S19).

Coformer	Contact	S	lurry experin	nents	Liquid-as	Co-	
	Preparation						sublimation
		<i>n</i> -Heptane	Pyridine	Diethyl ether	<i>n</i> -heptane	Diethyl ether	
Pyridoxine	Х	Х	n. a.	Х	Х	Х	Х
Methyl parabene	Х	х	n. a.	х	X	х	Х
Propyl parabene	Х	х	n. a.	х	Х	х	Х
t-Butyl-4-	n. a.	х	n. a.	Х	X	X	Х
hydroxyanisole							
Nicotinic Acid	n. a.	Х	n. a.	Х	X	Х	X
Nictoinamide	Х	X	n. a.	Х	X	Х	X
Oxalic Acid	n. a.	X	n. a.	Х	X	Х	X
Succinic Acid	n. a.	Х	n. a.	х	X	Х	X
cis-Aconitic Acid	Х	Х	n. a.	х	X	Х	X
Pyridine	n. a.	n. a.	Х	n. a.	n. a.	n. a.	n. a.

Table S2. Overview acetylsalicylic acid crystallisation results

n.a. – not attempted, x – physical mixture of the two compounds.



Figure S11. Comparison of experimental and from single crystal structure data simulated PXRD patterns of acetylsalicylic acid (red), **pyridoxine** and a physical mixture obtained from LAG grinding experiments.



Figure S12. Comparison of experimental and from single crystal structure data simulated PXRD patterns of acetylsalicylic acid (red), methyl paraben and a physical mixture obtained from LAG grinding experiments.



Figure S13. Comparison of experimental and from single crystal structure data simulated PXRD patterns of acetylsalicylic acid (red), propyl paraben and a physical mixture obtained from LAG grinding experiments.



Figure S14. Comparison of experimental and from single crystal structure data simulated PXRD patterns of acetylsalicylic acid (red), **t-butyl-4-hydroxyanisole** and a physical mixture obtained from LAG grinding experiments.



Figure S15. Comparison of experimental PXRD patterns of acetylsalicylic acid (red), **nicotinic acid** and a physical mixture obtained from LAG grinding experiments.



Figure S16. Comparison of experimental and from single crystal structure data simulated PXRD patterns of **acetylsalicylic acid** (red), nicotinamide and a physical mixture obtained from LAG grinding experiments.



Figure S17. Comparison of experimental PXRD patterns of acetylsalicylic acid (red), **oxalic acid** and a physical mixture obtained from LAG grinding experiments.



Figure S18. Comparison of experimental and from single crystal structure data simulated PXRD patterns of acetylsalicylic acid (red), **succinic aicd** and a physical mixture obtained from LAG grinding experiments.



Figure S19. Comparison of experimental PXRD patterns of acetylsalicylic acid (red), **cis-aconitic aicd** and a physical mixture obtained from LAG grinding experiments.

2.4 Carbamazepine (CARB) cocrystal screen

All **experimental cocrystals** (nicotinamide, oxalic acid, succinic acid) were **reproduced** in the experimental screen. Furthermore, new cocrystals were found with methyl parabene, t-butyl-4-hydroxyanisole and cis-aconitic acid (Table S3, Figure S21 - Figure S29). In case of propyl paraben one experiment resulted in a new pattern.

Coformer	Contact	Sluri	Slurry experiments			Liquid-assisted grinding		
	Preparation						sublimation	
		<i>n</i> -Heptane	Pyridi	Diethyl ether	<i>n</i> -heptane	Diethyl ether		
			ne					
Pyridoxine	Х	Х	n. a.	Х	Х	Х	X	
Methyl parabene	yes	yes	n. a.	yes	yes	yes	x	
Propyl parabene	Х	Inconclusive	n. a.	x	х	х	х	
t-Butyl-4-	n. a.	yes	n. a.	yes	yes	yes	x	
hydroxyanisole								
Nicotinic Acid	n. a.	X	n. a.	х	х	Х	х	
Nictoinamide	yes	yes	n. a.	yes	yes	yes	х	
Oxalic Acid	n. a.	yes	n. a.	yes	yes	yes	х	
Succinic Acid	n. a.	yes	n. a.	yes	yes	yes	х	
cis-Aconitic Acid	Х	yes	n. a.	yes	yes	yes	х	
Pyridine	n. a.	n. a.	X	n. a.	n. a.	n. a.	n. a.	

 Table S3. Overview carbamazepine crystallization results.

n.a. - not attempted, x - physical mixture of the two compounds. Inconclusive refers to the ambiguous

PXRD pattern observed in Figure S22



Figure S20. Contact preparation of nicotinamide-cocrystal-carbamazepine. At 126 °C and 160 °C the eutectic temperatures between nicotinamide and the cocrystal and carbamazepine and the cocrystal, respectively, can be seen.



Figure S21. Comparison of experimental and from single crystal structure data simulated PXRD patterns of carbamazepine (red), **pyridoxine** and a physical mixture obtained from LAG grinding experiments.



Figure S22. Comparison of experimental and from single crystal structure data simulated PXRD patterns of carbamazepine (red), methyl parabene and a cocrystal.



Figure S23. Comparison of experimental and from single crystal structure data simulated PXRD patterns of carbamazepine (red), **propyl parabene** and a physical mixture obtained from LAG grinding experiments.



Figure S24. Comparison of experimental and from single crystal structure data simulated PXRD patterns of carbamazepine (red), t-butyl-4-hydroxyanisole and a cocrystal.



Figure S25. Comparison of experimental and from single crystal structure data simulated PXRD patterns of carbamazepine (red), **nicotinic acid** and a physical mixture obtained from LAG grinding/slurry experiments.



Figure S26. Comparison of experimental and from single crystal structure data simulated PXRD patterns of carbamazepine (first), nicotinamide and a cocrystal (SDG and slurry).



Figure S27. Comparison of experimental and from single crystal structure data simulated PXRD patterns of carbamazepine (first), oxalic acid and a cocrystal (SDG and slurry).



Figure S28. Comparison of experimental and from single crystal structure data simulated PXRD patterns of carbamazepine (first), succinic acid and a cocrystal (slurry experiment).



Figure S29. Comparison of experimental and from single crystal structure data simulated PXRD patterns of carbamazepine (first), cis aconitic acid and a cocrystal (SDG and slurry).

Additional cocrystallization experiments were undertaken for the combination **carbamazepine** and **propyl parabene** (Table S4) with the aim to reproduce the phase seen in the initial *n*-heptane slurry experiments (**Figure S23**). Therefore, the range of solvents, molar ratios and crystallisation techniques was extended. None of the additional experiments resulted in a cocrystal.

Solvent / molar ratio (CBZ:PP)	1:1	2:1	1:2
Grinding (dr	y or liquid-assi	isted)	
dry	Х	X	х
dichloromethane	x, x ^a	Х	x
dichloroethane	Х	Х	x
diethyl ether	Х	Х	x
diisopropyl ether	Х	Х	x
acetone	Х	Х	x
methanol	Х	Х	x
<i>n</i> -butanol	X	X	х
ethyl acetate	Х	X	х
<i>n</i> -heptane	X	X	х
Slurry experim	entes (10 °C –	30 °C)	
Diethyl ether	X	n. a.	n. a.
diisopropyl ether	X	n. a.	n. a.
<i>n</i> -butanol	X	n. a.	n. a.
<i>n</i> -heptane	x, x ^a	n. a.	n. a.
Solvent evapora	ntion experimer	nts (RT)	
acetone	X	n. a.	n. a.
methanol	X	n. a.	n. a.
ethanol	X	n. a.	n. a.
<i>n</i> -butanol	X	n. a.	n. a.
ethyl acetate	X	n. a.	n. a.
acetonitrile	X	n. a.	n. a.
Cooling crysta	llisation exper	iments	
acetone	X	n. a.	n. a.
methanol	X	n. a.	n. a.
ethanol	X	n. a.	n. a.
<i>n</i> -butanol	X	n. a.	n. a.
ethyl acetate	X	n. a.	n. a.
acetonitrile	х	n. a.	n. a.

Table S4. Overview additional carbamazepine and propyl paraben cocrystallization results.

n.a. – not attempted, x – physical mixture of the two compounds. ^aTwo additional peak positions, otherwise physical mixture.

2.5 Rietveld refinements

DFT-d calculations (fixed cell and full optimization) were carried out with the CASTEP plane wave² code using the Perdew-Burke-Ernzerhof (PBE) generalized gradient approximation (GGA) exchangecorrelation density functional and ultrasoft pseudopotentials, with the addition of the Tkatchenko and Scheffler (TS) semi-empirical dispersion corrections.²⁰ Brillouin zone integrations were performed on a symmetrized Monkhorst–Pack k-point grid with the number of *k*-points chosen to provide a maximum spacing of 0.07 Å⁻¹ and a basis set cut-off of 560 eV. The self-consistent field convergence on total energy was set to $1x10^{-5}$ eV per atom. Energy minimizations were performed using the Broyden– Fletcher–Goldfarb–Shanno optimisation scheme within the space group constraints. The optimizations were considered complete when energies were converged to better than $2x10^{-5}$ eV per atom, atomic displacements converged to $1x10^{-3}$ Å, maximum forces to $5x10^{-2}$ eV Å⁻¹, and maximum stresses were converged to $1x10^{-1}$ GPa.

Carbamazepine: 3-t-butyl-4-hydroxyanisole BHA cocrystals (CARB:ESAL-A)

The fixed cell PBE-TS structure was used as the starting point for rigid body Rietveld refinements in TOPAS academic.³ The final refinements included a total of 54 parameters (28 profile, 4 cell, 1 scale, 1 isotropic temperature factor, 6 position and 6 rotation, 8 preferred orientation) yielding a final R_{wp} = 8.35%.

TITL CARB:ESAL-A

CELL 0.71073 9.5920 23.9589 10.6474 90 110.029 90 ZERR 4 0.0004 0.0007 0.0003 0 0.002 0 LATT 1 SYMM 1/2-x,1/2+y,1/2-z SFAC C H N O UNIT 104 112 8 12 **FVAR 1.00** O1 O Uiso 0.4853(5) -0.0337(3) 0.1643(10) 1.000 0.062(2) N1 N Uiso 0.4724(5) 0.0564(4) 0.2301(9) 1.000 0.062(2) N2 N Uiso 0.2621(5) -0.0007(3) 0.1612(8) 1.000 0.062(2) C1 C Uiso 0.3951(6) 0.0993(4) 0.2734(9) 1.000 0.062(2) C2 C Uiso 0.4092(5) 0.0052(3) 0.1843(9) 1.000 0.062(2) O2 O Uiso 0.342(3) 0.3804(6) 0.346(3) 1.000 0.062(2) O3 O Uiso 0.902(2) 0.3649(8) 0.308(3) 1.000 0.062(2) C3 C Uiso 0.6289(5) 0.0634(4) 0.2600(11) 1.000 0.062(2) C4 C Uiso 0.2887(6) 0.1316(3) 0.1789(10) 1.000 0.062(2) C5 C Uiso 0.4247(8) 0.1071(4) 0.4117(9) 1.000 0.062(2) C6 C Uiso 0.7245(6) 0.0614(5) 0.3943(12) 1.000 0.062(2) C7 C Uiso 0.6845(5) 0.0713(4) 0.1563(12) 1.000 0.062(2) C8 C Uiso 0.2061(7) 0.1709(3) 0.2199(10) 1.000 0.062(2) C9 C Uiso 0.3376(9) 0.1463(4) 0.4503(10) 1.000 0.062(2) C10 C Uiso 0.5423(8) 0.0780(5) 0.5144(9) 1.000 0.062(2) C11 C Uiso 0.6717(7) 0.0583(5) 0.5067(10) 1.000 0.062(2) C12 C Uiso 0.8785(6) 0.0647(5) 0.4197(13) 1.000 0.062(2) C13 C Uiso 0.8370(5) 0.0760(4) 0.1843(14) 1.000 0.062(2) C14 C Uiso 0.2302(9) 0.1779(4) 0.3560(10) 1.000 0.062(2) C15 C Uiso 0.9340(5) 0.0722(5) 0.3162(15) 1.000 0.062(2) C16 C Uiso 0.691(2) 0.3169(7) 0.330(3) 1.000 0.062(2) C17 C Uiso 0.763(2) 0.3667(7) 0.314(3) 1.000 0.062(2) C18 C Uiso 0.548(2) 0.3219(6) 0.337(3) 1.000 0.062(2) C19 C Uiso 0.768(2) 0.2597(7) 0.347(3) 1.000 0.062(2) C20 C Uiso 0.479(3) 0.3735(6) 0.333(3) 1.000 0.062(2) C21 C Uiso 0.692(3) 0.4183(7) 0.308(3) 1.000 0.062(2) C22 C Uiso 0.902(2) 0.2594(8) 0.479(3) 1.000 0.062(2) C23 C Uiso 0.6649(19) 0.2121(7) 0.355(2) 1.000 0.062(2) C24 C Uiso 0.822(2) 0.2465(7) 0.229(3) 1.000 0.062(2) C25 C Uiso 0.552(3) 0.4221(6) 0.318(3) 1.000 0.062(2) C26 C Uiso 0.263(2) 0.3314(6) 0.359(3) 1.000 0.062(2) H1 H Uiso 0.2197(5) -0.0401(3) 0.1443(8) 1.000 0.074(3) H2 H Uiso 0.2012(5) 0.0307(3) 0.1793(7) 1.000 0.074(3) H3 H Uiso 0.2708(6) 0.1253(3) 0.0733(10) 1.000 0.074(3) H4 H Uiso 0.6076(6) 0.0722(3) 0.0537(12) 1.000 0.074(3) H5 H Uiso 0.1224(8) 0.1955(3) 0.1453(11) 1.000 0.074(3) H6 H Uiso 0.3565(10) 0.1517(5) 0.5566(10) 1.000 0.074(3) H7 H Uiso 0.5290(10) 0.0762(6) 0.6119(9) 1.000 0.074(3) H8 H Uiso 0.7522(8) 0.0425(6) 0.5991(11) 1.000 0.074(3) H9 H Uiso 0.9540(6) 0.0628(6) 0.5228(14) 1.000 0.074(3) H10 H Uiso 0.8798(6) 0.0822(4) 0.1028(15) 1.000 0.074(3) H11 H Uiso 0.1640(10) 0.2078(4) 0.3885(11) 1.000 0.074(3) H12 H Uiso 1.0534(5) 0.0757(5) 0.3391(16) 1.000 0.074(3) H13 H Uiso 0.941(3) 0.4036(8) 0.312(3) 1.000 0.074(3) H14 H Uiso 0.491(2) 0.2841(6) 0.348(3) 1.000 0.074(3) H15 H Uiso 0.750(3) 0.4561(7) 0.297(3) 1.000 0.074(3) H16 H Uiso 0.958(2) 0.2186(9) 0.493(3) 1.000 0.074(3) H17 H Uiso 0.865(2) 0.2660(9) 0.565(3) 1.000 0.074(3) H18 H Uiso 0.983(2) 0.2920(9) 0.480(3) 1.000 0.074(3) H19 H Uiso 0.626(2) 0.2164(7) 0.440(2) 1.000 0.074(3) H20 H Uiso 0.5677(19) 0.2082(6) 0.264(2) 1.000 0.074(3) H21 H Uiso 0.7262(18) 0.1727(7) 0.369(2) 1.000 0.074(3) H22 H Uiso 0.8656(19) 0.2037(7) 0.239(3) 1.000 0.074(3) H23 H Uiso 0.910(2) 0.2751(8) 0.226(3) 1.000 0.074(3) H24 H Uiso 0.730(2) 0.2493(7) 0.133(3) 1.000 0.074(3) H25 H Uiso 0.501(3) 0.4628(6) 0.316(3) 1.000 0.074(3) H26 H Uiso 0.326(2) 0.3072(6) 0.449(3) 1.000 0.074(3) H27 H Uiso 0.159(2) 0.3456(6) 0.368(3) 1.000 0.074(3) H28 H Uiso 0.239(2) 0.3047(5) 0.270(3) 1.000 0.074(3) **END**



Figure S30. Overlay of the 30-molecule cluster of the observed structure of **CARB:ESAL-A** (colored by element, main disorder component only) and calculated PBE-TS structure (green, cell parameters fixed, atom positions optimized), $rmsd_{30}$ =0.07 Å.

Carbamazepine: 3-t-butyl-4-hydroxyanisole BHA cocrystals (CARB:ESAL-B)

The PBE-TS structure (fixed cell parameters) were used as the starting point for rigid body Rietveld refinements in TOPAS academic.³ The final refinements included a total of 61 parameters (28 profile, 4 cell, 1 scale, 1 isotropic temperature factor, 6 position and 6 rotation, 15 preferred orientation) yielding a final R_{wp} = 6.56%.

TITL CARB:ESAL-B

CELL 0.71073 12.6807 7.7880 23.3619 90 96.927 90 ZERR 4 0.0005 0.0003 0.0010 0 0.002 0 LATT 1 SYMM -x,1/2+y,1/2-z SFAC C H N O UNIT 104 112 8 12 **FVAR 1.00** O1 O Uiso 0.0278(12) 0.079(2) 0.2212(3) 1.000 0.076(4) N1 N Uiso 0.2087(12) 0.073(3) 0.2390(3) 1.000 0.076(4) N2 N Uiso 0.1116(13) 0.289(3) 0.2778(3) 1.000 0.076(4) C1 C Uiso 0.1886(11) -0.230(2) 0.2127(4) 1.000 0.076(4) C2 C Uiso 0.2054(10) -0.322(2) 0.1155(4) 1.000 0.076(4) O2 O Uiso 0.8398(12) 0.688(4) 0.0029(14) 1.000 0.076(4) O3 O Uiso 0.8505(9) 0.124(4) 0.1485(13) 1.000 0.076(4) C3 C Uiso 0.1851(11) -0.360(2) 0.1717(4) 1.000 0.076(4) C4 C Uiso 0.2315(9) -0.156(2) 0.1011(4) 1.000 0.076(4) C5 C Uiso 0.2388(9) -0.022(2) 0.1422(4) 1.000 0.076(4) C6 C Uiso 0.2788(9) 0.145(2) 0.1275(4) 1.000 0.076(4) C7 C Uiso 0.3359(10) 0.258(2) 0.1635(5) 1.000 0.076(4) C8 C Uiso 0.3671(11) 0.242(3) 0.2253(5) 1.000 0.076(4) C9 C Uiso 0.4613(12) 0.321(3) 0.2504(6) 1.000 0.076(4) C10 C Uiso 0.4969(14) 0.302(3) 0.3087(6) 1.000 0.076(4)

C11 C Uiso 0.4373(15) 0.208(3) 0.3443(5) 1.000 0.076(4) C12 C Uiso 0.3420(14) 0.133(3) 0.3211(4) 1.000 0.076(4) C13 C Uiso 0.3074(12) 0.149(3) 0.2622(4) 1.000 0.076(4) C14 C Uiso 0.2128(11) -0.062(2) 0.1979(3) 1.000 0.076(4) C15 C Uiso 0.1115(12) 0.146(2) 0.2455(3) 1.000 0.076(4) C16 C Uiso 0.9249(13) 0.809(4) 0.0089(15) 1.000 0.076(4) C17 C Uiso 0.7588(10) 0.444(4) 0.0388(13) 1.000 0.076(4) C18 C Uiso 0.8473(11) 0.553(4) 0.0412(14) 1.000 0.076(4) C19 C Uiso 0.9358(10) 0.519(4) 0.0810(15) 1.000 0.076(4) C20 C Uiso 0.9350(9) 0.375(4) 0.1164(14) 1.000 0.076(4) C21 C Uiso 0.8477(9) 0.265(4) 0.1133(13) 1.000 0.076(4) C22 C Uiso 0.7555(9) 0.299(4) 0.0742(13) 1.000 0.076(4) C23 C Uiso 0.6554(8) 0.186(4) 0.0719(12) 1.000 0.076(4) C24 C Uiso 0.5648(8) 0.254(3) 0.0278(11) 1.000 0.076(4) C25 C Uiso 0.6132(9) 0.185(4) 0.1312(11) 1.000 0.076(4) C26 C Uiso 0.6803(7) 0.001(4) 0.0549(12) 1.000 0.076(4) H1 H Uiso 0.0425(14) 0.354(3) 0.2807(4) 1.000 0.091(4) H2 H Uiso 0.1798(14) 0.342(3) 0.2970(4) 1.000 0.091(4) H3 H Uiso 0.1707(13) -0.256(3) 0.2564(4) 1.000 0.091(4) H4 H Uiso 0.2008(10) -0.423(2) 0.0830(5) 1.000 0.091(4) H5 H Uiso 0.1650(12) -0.490(2) 0.1835(5) 1.000 0.091(4) H6 H Uiso 0.2487(8) -0.128(2) 0.0574(4) 1.000 0.091(4) H7 H Uiso 0.2709(8) 0.176(2) 0.0815(4) 1.000 0.091(4) H8 H Uiso 0.3699(10) 0.368(2) 0.1435(5) 1.000 0.091(4) H9 H Uiso 0.5074(12) 0.397(3) 0.2231(7) 1.000 0.091(4) H10 H Uiso 0.5710(14) 0.362(3) 0.3265(7) 1.000 0.091(4) H11 H Uiso 0.4643(16) 0.195(4) 0.3902(5) 1.000 0.091(4) H12 H Uiso 0.2929(15) 0.062(3) 0.3484(4) 1.000 0.091(4) H13 H Uiso 0.9191(9) 0.122(4) 0.1743(14) 1.000 0.091(4) H14 H Uiso 0.9324(14) 0.872(4) 0.0515(15) 1.000 0.091(4) H15 H Uiso 0.9047(15) 0.906(4) -0.0247(15) 1.000 0.091(4) H16 H Uiso 1.0009(13) 0.749(4) 0.0019(16) 1.000 0.091(4) H17 H Uiso 0.6904(10) 0.477(4) 0.0081(13) 1.000 0.091(4) H18 H Uiso 1.0053(11) 0.602(4) 0.0850(15) 1.000 0.091(4) H19 H Uiso 1.0044(10) 0.347(4) 0.1472(15) 1.000 0.091(4) H20 H Uiso 0.4951(8) 0.170(3) 0.0284(11) 1.000 0.091(4) H21 H Uiso 0.5404(9) 0.385(3) 0.0381(11) 1.000 0.091(4) H22 H Uiso 0.5859(8) 0.254(3) -0.0165(11) 1.000 0.091(4) H23 H Uiso 0.5956(10) 0.316(4) 0.1445(11) 1.000 0.091(4) H24 H Uiso 0.6698(9) 0.128(4) 0.1650(12) 1.000 0.091(4) H25 H Uiso 0.5392(9) 0.111(3) 0.1286(11) 1.000 0.091(4) H26 H Uiso 0.6080(7) -0.078(4) 0.0529(11) 1.000 0.091(4) H27 H Uiso 0.7084(7) -0.005(4) 0.0123(12) 1.000 0.091(4) H28 H Uiso 0.7410(8) -0.059(4) 0.0860(12) 1.000 0.091(4) **END**



Figure S31. Overlay of the 30-molecule cluster of the observed structure of **CARB:ESAL-B** (colored by element, main disorder component only) and calculated PBE-TS structure (green, cell parameters fixed, atom positions optimized), $rmsd_{30}$ =0.08 Å.

Carbamazepine:methyl paraben CEBG cocrystals (CARB-CEBG-A)

The fixed cell PBE-TS structure was used as the starting point for rigid body Rietveld refinements in TOPAS academic.³ The final refinements included a total of 54 parameters (26 profile, 6 cell, 1 scale, 1 isotropic temperature factor, 6 position and 6 rotation, 8 preferred orientation) yielding a final R_{wp} = 7.62%.

TITL CARB-CEBG-A

CELL 0.71073 6.6607 8.4157 17.7876 89.651 87.906 87.519 ZERR 2 0.0002 0.0003 0.0006 0.003 0.003 0.004 LATT 1 SFAC C H N O UNIT 46 40 4 8 **FVAR 1.00** O1 O Uiso 0.6188(17) -0.201(2) 0.2401(8) 1.000 0.076(4) N1 N Uiso 0.7326(15) 0.019(2) 0.1784(8) 1.000 0.076(4) N2 N Uiso 0.6140(19) 0.035(3) 0.3037(8) 1.000 0.076(4) C1 C Uiso 0.6826(12) -0.126(2) 0.0617(8) 1.000 0.076(4) C2 C Uiso 0.9581(13) -0.279(3) 0.0018(10) 1.000 0.076(4) O2 O Uiso 0.558(11) 0.126(5) 0.571(2) 1.000 0.076(4) O3 O Uiso 0.362(10) 0.599(4) 0.299(2) 1.000 0.076(4) C3 C Uiso 0.7560(13) -0.227(2) 0.0042(9) 1.000 0.076(4) O4 O Uiso 0.871(11) 0.198(6) 0.534(2) 1.000 0.076(4) C4 C Uiso 1.0863(13) -0.227(3) 0.0556(10) 1.000 0.076(4) C5 C Uiso 1.0169(13) -0.123(3) 0.1136(10) 1.000 0.076(4) C6 C Uiso 1.1568(14) -0.068(3) 0.1680(10) 1.000 0.076(4) C7 C Uiso 1.1487(16) 0.073(3) 0.2053(10) 1.000 0.076(4) C8 C Uiso 1.0000(17) 0.204(3) 0.1981(10) 1.000 0.076(4)

C9 C Uiso 1.056(2) 0.362(3) 0.2065(10) 1.000 0.076(4) C10 C Uiso 0.921(2) 0.490(3) 0.1935(10) 1.000 0.076(4) C11 C Uiso 0.726(2) 0.462(2) 0.1712(9) 1.000 0.076(4) C12 C Uiso 0.6652(17) 0.306(2) 0.1652(8) 1.000 0.076(4) C13 C Uiso 0.7994(16) 0.178(3) 0.1800(9) 1.000 0.076(4) C14 C Uiso 0.8106(13) -0.077(3) 0.1167(9) 1.000 0.076(4) C15 C Uiso 0.6538(17) -0.056(2) 0.2420(8) 1.000 0.076(4) C16 C Uiso 0.952(11) 0.113(7) 0.598(2) 1.000 0.076(4) C17 C Uiso 0.598(10) 0.299(5) 0.465(2) 1.000 0.076(4) C18 C Uiso 0.669(11) 0.199(5) 0.528(2) 1.000 0.076(4) C19 C Uiso 0.395(10) 0.296(4) 0.4458(19) 1.000 0.076(4) C20 C Uiso 0.724(10) 0.404(5) 0.425(2) 1.000 0.076(4) C21 C Uiso 0.649(10) 0.503(5) 0.369(2) 1.000 0.076(4) C22 C Uiso 0.445(10) 0.501(4) 0.351(2) 1.000 0.076(4) C23 C Uiso 0.320(10) 0.394(4) 0.3893(19) 1.000 0.076(4) H1 H Uiso 0.550(2) -0.017(3) 0.3506(8) 1.000 0.091(4) H2 H Uiso 0.648(2) 0.152(3) 0.3051(8) 1.000 0.091(4) H3 H Uiso 0.5250(12) -0.086(2) 0.0657(7) 1.000 0.091(4) H4 H Uiso 1.0152(15) -0.361(3) -0.0419(10) 1.000 0.091(4) H5 H Uiso 0.6555(13) -0.266(2) -0.0384(8) 1.000 0.091(4) H6 H Uiso 1.2442(13) -0.268(3) 0.0535(11) 1.000 0.091(4) H7 H Uiso 1.2904(15) -0.146(3) 0.1754(11) 1.000 0.091(4) H8 H Uiso 1.2757(17) 0.098(3) 0.2400(11) 1.000 0.091(4) H9 H Uiso 1.208(2) 0.386(3) 0.2226(11) 1.000 0.091(4) H10 H Uiso 0.966(3) 0.611(3) 0.2012(11) 1.000 0.091(4) H11 H Uiso 0.623(2) 0.563(2) 0.1606(9) 1.000 0.091(4) H12 H Uiso 0.5125(16) 0.281(2) 0.1505(8) 1.000 0.091(4) H13 H Uiso 0.462(10) 0.676(4) 0.278(2) 1.000 0.091(4) H14 H Uiso 0.896(11) 0.169(7) 0.650(2) 1.000 0.091(4) H15 H Uiso 1.115(11) 0.122(7) 0.591(3) 1.000 0.091(4) H16 H Uiso 0.914(11) 0.025(6) 0.597(2) 1.000 0.091(4) H17 H Uiso 0.298(10) 0.216(4) 0.4768(18) 1.000 0.091(4) H18 H Uiso 0.880(10) 0.410(6) 0.440(2) 1.000 0.091(4) H19 H Uiso 0.746(10) 0.587(5) 0.339(2) 1.000 0.091(4) H20 H Uiso 0.163(10) 0.392(4) 0.3746(18) 1.000 0.091(4) **END**



Figure S32. Overlay of the 30-molecule cluster of the observed structure of **CARB-CEBG-A** (colored by element, main disorder component only) and calculated PBE-TS structure (green, cell parameters fixed, atom positions optimized), $rmsd_{30}$ =0.09 Å.

cis Aconitic acid (form II)

The PBE-TS structure (fixed cell parameters) were used as the starting point for rigid body Rietveld refinements in TOPAS academic.³ The final refinements included a total of 58 parameters (38 profile, 4 cell, 1 scale, 1 isotropic temperature factor, 3 position and 3 rotation, 8 preferred orientation) yielding a final R_{wp} = 8.02%. Note that only one position of the likely disordered COOH function was refined.

TITL cis Aconitic acid (form II)

CELL 0.71073 25.2072 4.91846 11.5654 90 97.8134 90 ZERR 8 0.0008 0.00014 0.0004 0 0.0015 0 LATT 7 SYMM -x,y,1/2-z SFAC C H O UNIT 48 48 48 **FVAR 1.00** O1 O Uiso 0.2531(2) 0.9545(14) 0.4151(6) 1.000 0.0414(14) O2 O Uiso 0.1331(2) 0.8155(11) 0.4378(5) 1.000 0.0414(14) O3 O Uiso 0.2015(3) 1.3319(12) 0.3931(6) 1.000 0.0414(14) O4 O Uiso 0.08025(18) 0.5533(8) 0.3086(4) 1.000 0.0414(14) O5 O Uiso 0.0450(2) 1.0372(6) 0.1224(5) 1.000 0.0414(14) O6 O Uiso 0.03986(17) 0.7218(5) -0.0199(4) 1.000 0.0414(14) C1 C Uiso 0.1862(2) 0.9939(10) 0.2485(6) 1.000 0.0414(14) C2 C Uiso 0.11915(17) 0.7286(7) 0.1166(5) 1.000 0.0414(14) C3 C Uiso 0.14327(19) 0.8300(9) 0.2343(5) 1.000 0.0414(14) C4 C Uiso 0.2157(2) 1.0876(12) 0.3623(6) 1.000 0.0414(14)

C5 C Uiso 0.11900(19) 0.7359(9) 0.3379(4) 1.000 0.0414(14) C6 C Uiso 0.06459(18) 0.8433(6) 0.0747(5) 1.000 0.0414(14) H1 H Uiso 0.06791(18) 0.4772(9) 0.3800(4) 1.000 0.0498(16) H2 H Uiso 0.00379(18) 0.8190(5) -0.0516(4) 1.000 0.0498(16) H3 H Uiso 0.2033(2) 1.0697(10) 0.1726(6) 1.000 0.0498(16) H4 H Uiso 0.14402(18) 0.7875(8) 0.0499(5) 1.000 0.0498(16) H5 H Uiso 0.11660(15) 0.5053(7) 0.1146(4) 1.000 0.0498(16) H6 H Uiso 0.2231(3) 1.3950(13) 0.4704(7) 1.000 0.0498(16) END



Figure S33. Overlay of the 15-molecule cluster of the observed structure of **cis Aconitic acid form II** (colored by element, main disorder component only) and calculated PBE-TS structure (green, cell parameters fixed, atom positions optimized), rmsd₁₅=0.14 Å.

References

Etter, M. C.; MacDonald, J. C.; Bernstein, J., Graph-set analysis of hydrogen-bond patterns in organic crystals. *Acta Crystallographica, Section B: Structural Science* 1990, *B46* (2), 256-262.
 Clark, S. J.; Segall, M. D.; Pickard, C. J.; Hasnip, P. J.; Probert, M. J.; Refson, K.; Payne,

M. C., First principles methods using CASTEP. Zeitschrift fur Kristallographie 2005, 220 (5-6), 567-570.

3. Coelho, A. A. *Topas Academic V5*, Coelho Software: Brisbane, 2012.